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Abstract
Sarah S. Goderecci
CYTOTOXIC AND ANTIMICROBIAL EFFECTS OF SILVER-CONTAINING
SURFACES
2016 - 2017
Gregory A. Caputo, Ph.D.
Master of Science in Pharmaceutical Sciences
This study examines applications of sputtered silver coatings as alternatives to
traditional antibiotic treatments. Given the increase in reports of antibiotic-resistant
bacteria, new treatments and coatings for in-dwelling medical devices such as catheters
and orthopedic implants are necessary. Silver oxide films were deposited onto Ti surfaces
to examine the efficacy of such coatings against a variety of bacterial species both in
vitro and in vivo. Bacterial growth studies showed that coatings exhibited antimicrobial
activity against a range of bacterial species acting either in a bacteriostatic or bactericidal
mechanism, depending on the target. Limited toxicity to in vitro mammalian cells was
evident in the immediate area proximal to the disc and preliminary studies in a murine
infection model show the ability of immunocompetent animals to clear silver from the
system. In addition, AgO was examined as an additive to silk biopolymers to add
antimicrobial activity for future application in liquid bandages. Silver oxide sputtered
films were applied to standard bandages to compare their efficacy to that of commercially
available antibiotic-loaded bandages. Silver oxide/copper oxide mixtures were sputtered
onto high-density polyethylene to determine efficacy and potentially modulate Ag+
release rates. Preliminary results of these studies indicate that AgO-impregnated
biopolymers, silver oxide-sputtered silk films, silver bandages and silver oxide/copper
oxide mixtures exhibited some efficacy against a variety of bacterial species.
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Chapter 1
General Introduction
Antibiotic Resistance
Since earliest recorded history, civilizations understood the importance of
eliminating harmful bacteria and preventing infections, although it was impossible to
fully understand the cause of such diseases. It was the discovery of Penicillin in 1928 that
led to the “Golden Age” of antibiotic development; multiple new antibiotic drugs were
discovered, leading people to believe that all infectious diseases could be cured using
antimicrobial drugs2. Only ten years following the beginning of penicillin treatment, it
was identified that a number of bacteria from the Typhoid-coli group of were not
inhibited by the antibiotic, thought to be due to their ability to produce an enzyme3-4 that
was able to degrade the antibiotic. Emergence of antibiotic resistance has followed the
development of each new antimicrobial drug since that time, and has become an
increasingly devastating and equally challenging obstacle to overcome.
Antimicrobial resistance has proven a worldwide problem, despite differences in
application and availability of specific antibiotic drugs in different areas of the world. In
the United States alone, the Center for Disease Control estimated that at least 2 million
people are infected with antibiotic-resistant bacteria each year, with at least 23,000 dying
as a direct result5. Although sometimes difficult to quantify the size and scope of
resistant infections, one study estimates the cost of treating ear infections alone as having
increased 20% between 1997 and 1998, costing approximately $216 million. In this
study, infections were caused by only three bacterial species: S. pneumoniae, H.
influenzae, and M. catarrhalis6; this study provides a small glimpse into the true cost of

antibiotic resistance, yet the larger picture has the potential to be far more devastating. In
addition, because of the financial burden associated with resistance development, there
has been a lack of new drugs in the development pipeline, which poses an even greater
impact for antibiotic resistance. These factors are among the many that are prompting
research into alternative antimicrobial approaches, including shifting the focus from
antibiotic treatments to infection control and therapies that have reduced likelihood of
resistance development in an attempt to combat further diminished effects of current
antibiotics.
Understanding the mechanisms by which bacteria overcome an antibiotic is the
first step in finding alternative therapies. The ability of many types of bacteria to quickly
adapt and evolve is one of the underlying mechanisms used to develop resistance.
Antibiotic resistance development can be classified in two broad categories: intrinsic or
acquired resistance. In the case of intrinsic resistance, the inherent, molecular, and
physiological composition of the bacteria presents barriers to the action of an antibiotic.
Most notably, membrane permeability, or the lack of specifically targeted enzymes, is the
most common causes of intrinsic resistance. Acquired resistance, however, is much more
complex. In this scenario, the bacterium has come into contact with a plasmid that
contains determinants for resistance, or the bacterium previously underwent a
chromosomal mutation, which would allow it to be resistant to the antibiotic. At this
point, the mechanisms for resistance become dependent on the plasmid acquired or the
mutation2. One such example of plasmid-mediated antibiotic resistance is quinolone
resistance, which was thought to originate from a genetic mutation, yet the discovery a
multi-resistant plasmid with the ability to encode for quinolone resistance has changed

the general understanding of the underlying mechanism of this type of resistance7. The
downstream effects of these genetic alterations result in either enzyme production to
degrade the drug, modification of the drug target, and/or enhanced active export of the
drug2.
When prescribed an antibiotic for an illness, patients are instructed to take the
correct dosage each day for a set number of days to ensure that the source of the infection
is completely eradicated. In some cases, whether due to antibiotic misuse, overuse, or due
to bacterial survival mechanisms, viable bacteria remain in the patient even after
treatment. More recent studies have suggested that bacteria can also overcome antibiotics
collectively8, rather than only some individuals surviving to replicate and produce an
infection requiring stronger antibiotic treatment. Regardless of the amount of bacteria that
become tolerant to treatment, antibiotic tolerance is a definite precursor to resistance, and
should be taken into account by prescribers and patients alike.
Overprescribing antibiotics has become a major cause of resistance development,
especially in wealthier nations where antibiotics are more easily available. Worldwide
antibiotic consumption is a rising trend, and the over-the-counter availability in some
nations has increased usage in those areas, even despite the medication’s high cost9. In
China, some hospitals are offered an incentive for antibiotic sales, which drives
overprescribing; one study estimated that ¼ of the total revenue for two hospitals was
exclusively due to the sale of antibiotics10. The World Health Organization published a
study in 2014 analyzing bacterial resistance in 129 nations with a variety of average
income levels. The data shows that a majority of the resistant cases of E. coli, K.
pneumoniae, and S. aureus originated in upper-middle income or high-income nations,

but no reports were available for low income or low-middle income countries. This
report, although helpful, highlights another inconsistency in the available data: there is no
protocol in reporting antibiotic-resistant cases globally, and therefore no comprehensive
data on the scope of resistance across the globe1. In addition, the World Health
Organization estimates that the size and scope of antibiotic resistance to classes such as
beta-lactams (Figure 1) is affecting the population on a worldwide scale.
The use of antibiotics in agriculture and food production is another major factor in
the growth and spread of resistance. Extensive research has been done as to the
mechanism of growth benefit when administering sub-therapeutic levels of antibiotics to
food-producing animals. Hypotheses of these studies include the inhibition of harmful
bacteria which may be mildly pathogenic, inhibition of bacterial urease, improved
efficiency of the gut, nutrient sparing, improved nutrient absorption from morphological
changes to small intestinal epithelium, and reduced immune stimulation11. One study
shows an estimated 70% of antibiotics used in the United States are consumed by
animals, as compared to the 50% used for agricultural purposes internationally12. As
explained previously, agricultural antibiotic administration poses the risk of enteric
bacteria in these animals developing tolerance to the administered drugs. This introduces
the prospect of antibiotic resistance developing across multiple species, and in 2014 there
were multiple gene discoveries in food-producing species that code for antibiotic
resistance13. Regardless of the benefits of antibiotic administration in agricultural
settings, it has been confirmed by one extensive study that the use of antibiotics in foodproducing animals can translate antimicrobial resistance profiles to humans that consume
them14. In many cases, antibiotic-resistant genes have been found in both packaged meat

and human isolates15; bacteria, after ingestion by consumption or preparation, have been
found to survive in the human body for up to fourteen days16, enough time to induce
infection in its host.
Health and Medical Devices
In 2011, the CDC estimated that 721,800 hospital infections occurred in the
United States, accounting for 1 in every 25 hospitalized patients that year17. Of these
infections, pneumonia and surgical site infections occurred in the highest number of cases
(22%), followed by gastrointestinal infections (17%), urinary tract infections (13%), and
bloodstream infections (11%). In these cases, some of the most common causes of these
infections were C. difficile (12%), methicillin-resistant S. aureus (MRSA) (11%) and E.
coli (9%). Although recent reports show that hospital-acquired infection rates are on the
decline18, alternatives to traditional cleaning procedures and treatments are becoming
widely investigated.
Preventing infections has become a goal of both the scientific and medical
communities in an attempt to reduce antibiotic usage and stop the spread of resistance.
This practice is becoming increasingly common in the realm of orthopedic surgeries, due
to the difficulty of treatment and clearance of osteomylytic infection (interior of the
bone). Stronger antibiotic courses as well as implant retrieval/replacement are common in
implant-related osteomyelitis. As such, surgical intervention related to infection control
yields negative outcomes such as patient stress and prolonged hospital stay, all of which
can cost upwards of $50,000 per instance19.

Infections in orthopedic surgeries have become increasingly more prevalent due
to the ability of bacteria to adhere to the surface of the implant20, although the body’s
natural immune defenses are boosted following surgical stresses. Should enough bacterial
cells adhere to the surface of the implant in close special arrangement, biofilms can be
created on the surface of the implant21. Briefly, biofilms, whether made up of a single
bacterial division or multiple species, have proven far more resistant to standard
antibiotic treatments, and in most cases, removal and replacement of the implant is the
only viable option for complete recovery. The mechanism in which biofilms resist
antibiotic activity is somewhat variable between species, yet in the case of P. aeruginosa,
for example, it was found that periplasmic glucans synthesized by the bacteria have the
ability to interact directly with administered antibiotics, which prevents them from
reaching their site of action22. This mechanism of resistance is only one example of how
biofilms can resist antimicrobials, making them anywhere from 10-1,000 times more
difficult to irradiate than the planktonic bacteria23. In the United States alone, the total
yearly cost for treatment of biofilm infections is estimated to be $94 billion, while
infections are responsible for half a million deaths24.
There are multiple proposed methods for preventing infections post-surgery,
including preventing bacterial adhesion and absorption, various methods to kill bacteria,
and ‘smart coatings’ for implants25. Of these, the practice of applying a surface coating
to the implant has become the most popular, due to lack of continued maintenance and
near-identical surgical procedure as that of a non-coated implant26. Coating orthopedic
implants could potentially inhibit bacteria from adhering to the surface of the implant,
therefore preventing or reducing biofilm growth and therefore, subsequent infection.

Silver as an Antimicrobial
Silver was first documented as having been used by early civilizations as a water
purification tool; silver coins and silver vessels were used to hold and purify collected
water27. The first documented medical use of silver occurred between 705-750 CE,
although it was most likely used prior to that time for medicinal purposes. Despite the
lack of knowledge by early civilizations about microbial infections, it became
overwhelmingly evident that silver therapies were viable cures for various conditions. In
the following years, silver was used as treatments for eye infections, surgical dressings,
burn wounds, ulcer treatments, and compound fractures28-29. The first silver-resistant
bacteria were identified in the 1960s from a burn wound treated with silver nitrate30, and
have since been identified in both clinical settings as well as environments where silver is
naturally-occurring31-32. The resistance mechanism, although not completely understood,
is thought to be similar to resistance mechanisms of bacteria against others metals (Cu,
Zn, etc.)32, and although published evidence is scarce, has only been associated with high
quantities of silver over frequent time periods33.
Silver’s antimicrobial properties arise from the presence of the silver ion (Ag+)33,
although the exact mechanism of action is still unknown. Many proposed theories on the
mechanism of action of Ag+ deal with interactions at the bacterial cell membrane, which
can affect membrane permeability, cause inhibition of both the proton motive force and
respiratory transport chain, all of which result in cell death27, 33-34. Based on suspected
mechanisms, silver can be considered a viable candidate for broad-spectrum
antimicrobial activity, despite not knowing the frequency or identity of its targets.

There are multiple delivery methods and product forms of silver on today’s
market, yet the common element between each is the delivery of silver ions to the
affected area. Selected product forms are also dependent on the context in which silver is
being administered, the solubility profile of the environment, and longevity of activity.
Currently, silver nanoparticles are considered an efficient method of delivery, largely due
to their customization profiles and variability. In addition, colloidal silver has been a
popular ‘cure-all’ remedy, and can be purchased in any number of places. Silver
inorganic complexes, such as silver sulfadiazine, silver nitrate, silver chloride, and silver
oxide are also particularly favorable35 but can be difficult to administer due to low
solubility in water.
Silver Toxicity in Humans
Although silver is found in many aspects of the environment, it is not considered
naturally occurring in the human body, nor is it acknowledged as a trace element.
Absorption through food and drink can provide detectable low levels of silver in the
bloodstream36, these levels have not proven to impact normal function, nor cause
excessive buildup in organ tissues37. In cases of prolonged silver exposure or extended
treatment, the most widely-reported side effect is a blue-gray discoloration of the skin or
soft tissue, referred to as argyria38. In cases such as these, silver accumulation was
reported in such tissues as the skin, kidneys, liver, corneas, mucous membranes, nails,
and spleen37, 39-40 although in the majority of cases, silver deposition was merely
cosmetic, and is not known to be life-threatening41.

There is some concern regarding the possible neurotoxicity of silver, as well as
the ability of silver ions to cross the blood-brain barriers and induce negative neurologic
effects42-43. There are at least nine known metals that have been found to accumulate at
the blood-brain barrier and gain access to neurologic tissues, including the toxic metals
lead, cadmium, and mercury41-42. Silver-induced neurotoxicity is believed to be rare43,
however one clinical study showed the effect of colloidal silver as a nasal spray for 2-5
years on an elderly patient. In a necropsy examination of the brain, significant silver
deposits were found in only part of the choroid plexus portion, while the majority of brain
parenchyma tissue appeared normal43-44. Further investigation of the possible
neurotoxicity of silver are needed before definitive determinations can be made regarding
the safety of silver therapy over extended periods of time.
Our Study
Adding a coating to the surface of titanium implants has become an increasingly
popular tactic in dealing with infection caused from surgery45. Previous work has shown
that using a sputtering technique, silver can be applied in thin coatings to titanium
surfaces with good adherence, and such coatings were shown to prevent bacterial
adhesion to the surface46. The goal of this work was to develop and characterize coatings
that can adhere to surfaces appropriate for medical devices, elute some or all of the
material from the coating as an antimicrobial in solution, and develop an understanding
of the release dynamics of the eluted materials. Using a modified reactive-sputtering
approach, we have applied silver oxide coatings that retain the same materials properties
as pure silver coatings, but can also elute Ag+ from the surface, which act as an
antimicrobial in solution. Coatings that elute from a surface are useful in healthcare

applications due to their ability to not only prevent adhesion of bacteria to the surface, but
to kill any bacteria in the immediate area, allowing for maximal wound healing with
minimal or no antibiotic intervention. This coating approach is potentially useful for
titanium orthopedic implants as well as catheters, medical instruments, hospital surfaces,
and other objects at high-risk for bacterial contamination and/or infection.
Silver-coated titanium. Silver-sputtered titanium discs, used to simulate
orthopedic implants, were subsequently tested for antibacterial activity in solution.
Coatings containing different thickness and chemical composition were tested against a
variety of bacterial species to assess broad-spectrum antimicrobial efficacy, as supported
by previous results from our lab and the literature. In addition, release rates of silver from
the coated discs in various media types were studied to determine any relationship
between rate of release and antimicrobial activity. Furthermore, efficacy and toxicity
studies are ongoing to assess how sputtered coatings react in in vitro and in vivo systems
using mammalian cell culture models, as well as a murine infection model.
Alternative modes of silver delivery. Silk is a biocompatible protein polymer,
derived from biological sources which degrades into non-toxic products in vivo47, making
it ideal for biomaterial delivery systems. Silk solutions formulated from Bombyx mori
caterpillar cocoons were treated and formulated to include various percentages of silver
oxide, or coated with silver oxide deposited via reactive sputtering. To assess the
antimicrobial properties of the impregnated and coated silk material, films were deposited
on the bottom of 96 well plates for analysis. Release rates and antimicrobial properties
for these films were assessed in solution against various bacterial species. To extend the
scope of applications for these coatings, silver-coated bandages were also investigated,

and were compared against standard bandages and commercially available antibioticloaded bandages. Current and ongoing experiments are focusing on the antimicrobial
properties of copper and copper oxide/silver oxide mixtures. Copper oxide’s poor
solubility profile proved to affect its antimicrobial efficiency, whereas the silver
oxide/copper oxide mixtures were the most effective in killing bacteria.

Figure 1. Resistance to beta-lactam antibiotics 1.

Chapter 2
Antimicrobial Activity of Silver Oxide Containing Thin Films
Introduction
Antimicrobial resistance has proven to be an obstacle of overwhelming
importance to both the medical and scientific communities following the introduction of
antibiotics in the early 20th century2. The ability of many bacteria to adapt to changing
environmental conditions can be at least partly a result of their ability to overcome
pharmaceutical approaches intended to eradicate them. Routine and improper antibiotic
use is partially responsible for the selective pressure that ultimately provides advantages
for mutant bacterial strains; those strains have proven far more costly to treat, and often
require longer hospital stays in comparison to strains that are susceptible to traditional,
small-molecule antibiotic treatments4. In addition, intrinsic resistance is another factor in
the resistance cascade: the low membrane permeability of certain bacterial strains makes
antibiotic penetration of the membrane nearly impossible2.
Preventing infections is a goal of both the scientific and medical communities in
an attempt to reduce antibiotic usage and stop the spread of resistance. Infection control
has become a significant concern in many areas of medicine but is especially critical in
orthopedic surgery due to the invasive measures that must be taken when infections
develop post-surgery which are extremely difficult to treat with antibiotics alone. The
restricted access around surgical implants results in the need for stronger and longer
antibiotic courses and increased potential for implant retrieval, debridement and device
replacement. Additional surgeries result in increases in patient stress and prolonged
hospital stay19. Some studies estimate that 2.5% of primary hip and knee arthroplasties

and up to 20% of revision arthroplasties develop a periprosthetic joint infection, with the
mortality rate for these infections nearly 2.5%9. Current research estimates that if there
are no successful efforts to combat the spread of resistance, the number of annual deaths
could increase from the current 700,000 to as many as 10 million by the year 205048.
Silver has been used for thousands of years in different civilizations for numerous
applications including food and water purification, ulcer treatments, promoting wound
healing, as well as prevention of surgical infections29. Antimicrobial studies using silver
compounds show its efficacy against a wide range of bacterial species including B.
subtilis, E. coli, P. aeruginosa, P. vulgaris, and S. aureus49-52. The exact antimicrobial
mechanism of silver is not fully elucidated, but the ability of silver to act against multiple
bacterial species suggests that silver interacts with multiple bacterial target sites, most
readily with the thiol groups of cysteine residues53. This is consistent with the high
abundance of thiol groups in bacterial cell membranes, and silver exhibiting a broadspectrum antimicrobial activity profile. At the bacterial cell membrane, ionic silver
inhibits the proton motive force (PMF), the respiratory electron transport chain, and
affects membrane permeability, all of which can result in cell death27, 33-34. Although
different forms of silver are available, the ones most readily available fall into three
categories: elemental silver, inorganic silver complexes, and organic silver complexes33.
Many varieties of silver materials are used in both healthcare and medical device
industry, yet the release of silver ions from the complex is what ultimately determines the
compound’s antimicrobial efficacy54. The primary drawback of pure silver is the poor
aqueous solubility, which limits the ability to act as an antimicrobial over meaningful
distances from metallic surfaces. Considering the silver ion Ag+ is the likely

antimicrobial form, efficient solubilization in the environment is necessary for activity
beyond the surface46. There are a variety of silver-containing complexes that enhance the
solubility of silver54. Silver oxide has low solubility in water, however it generates
enough soluble silver ions to effect antimicrobial activity in several applications55-56. Our
previous work has shown that silver oxide can be efficiently deposited as thin-film
coatings on a variety of surfaces and retains the ability to generate sufficient
concentrations of Ag+ to exert antimicrobial activity57.
Thin film coatings of silver oxide can be applied to orthopedic implants in an
effort to inhibit bacteria from attaching to the surface of the implant, therefore
preventing/reducing biofilm growth and subsequent infection. The solubility of silver
oxide also allows for antimicrobial activity distal to the implant surface, which can
ameliorate infections in the area of the implant. To further examine the antimicrobial
efficacy of the silver oxide thin film coatings, parameters such as coating thickness, rate
of release of silver ions from the surface, and initial cytotoxicity to in vitro mammalian
cell systems were investigated. The work reported here indicates that relatively short
exposure of silver oxide thin films to a culture was sufficient to inhibit bacterial growth.
Additionally, the release of Ag+ ions from the films was not significantly impacted by the
culture medium, but efficacy and toxicity were related to total silver concentration in
solution.
Materials and Methods
Generation of silver-containing films. Thin films of cubic silver oxide (AgO)
were grown reactively in a custom designed two-cathode sputter deposition chamber.

Each of the cathodes contains a two-inch diameter silver target with 99.95% purity. The
cathodes are in a confocal configuration pointing upward toward a sample holder that is
2.54 cm x 5.08 cm. The gas mixture used is 67% argon and 33% oxygen adjusted using
two mass flow controllers. Argon is adjusted to a rate of 20 sccm while oxygen flows at a
rate of 10sccm, though other mixtures of argon and oxygen also will work to synthesize
bactericidal silver oxide. The pressure in the chamber during deposition is held at
20mTorr controlled by a butterfly baffle valve connected to a capacitance manometer.
The chamber is configured with a 360l/s turbopump and backed with a Drytel 1025
vacuum pump. The working distance, the distance from the silver target to the substrate,
is approximately 8.89 cm.
Each of the cathodes is powered using a MDX-500 DC-power supply applying a
power of 25 W to each cathode. In the chamber configuration, the deposition rate is
approximately 17 nm/min. X-ray diffraction results indicate that the coatings are a
combination of cubic phases of AgO and Ag2O (henceforth referred to as AgxO)57. The
microstructure of the coatings is measured using a field emission scanning electron
microscope (JEOL 7500).
Bacterial culturing. Bacteria were streaked onto LB - miller agar (Difco) plates
from strains stored in a frozen library (E. coli MG1655, S. aureus ATCC® 25923, P.
aeruginosa ATCC10145, K. pneumoniae 700603). All streaks were stored in a
refrigerator at 4°C. To prepare overnight cultures, a single colony of each bacterial strain
was added to LB broth (Difco) in sterile culture tubes. Tubes were placed in the shaking
incubator at 37°C overnight to allow for sufficient bacterial growth. Following the
incubation period, dilutions of the overnight culture were made in Muller-Hinton broth

(Criterion) 1:100; changing broth provides for better short-term bacterial growth and
facilitates comparisons to MIC assay protocols.
Bacterial growth analysis. Dilutions were grown to OD600 0.2 - 0.3 before being
diluted a second time to the indicated experimental range. Calculations were performed
under the assumption that OD600 = 1.0 is equivalent to ~108 CFU/mL for S. aureus and K.
pneumoniae and ~109 CFU/mL for E. coli and P. aeruginosa58-60. The bacteria were
added to fresh Muller-Hinton broth in sterile tubes containing the test piece; total volume
in each tube was 3 mL. All experiments with silver-coated discs were performed in at
least duplicate for each bacterial species tested. OD600 measurements were recorded on
each of the cultures every 30 min using ultraviolet-visible spectroscopy; between time
intervals, tubes were agitated at 220 RPM in a shaking incubator at 37°C.
Growth in cultures pre-incubated with silver. To prepare silver-soaked broth
solutions, MH broth was added to each of the sterile culture tubes, and tubes were placed
in the shaking incubator at 37°C. AgxO-coated titanium discs were added to each of the
tubes at varying time intervals to allow for dissolution of the coating into the solution.
Following the selected time periods, the pre-incubated silver-containing broth was
transferred to new, sterile tubes. Following the growth of the bacterial dilutions to OD600
0.1 - 0.2, 30 µL bacterial solution was added to each of the pre-incubated broth tubes and
the experiment carried out as described. At three different equally spaced time intervals
during the kinetics assay, 3 µL was taken from each test tube and plated on LB agar in
various positions to assess bacterial growth at those times. Plates were incubated
overnight at 37°C.

Zone of inhibition (ZOI) assay. Dilutions were grown to OD600 0.1 - 0.2.
Subsequently, 100 µL of bacteria was plated onto lysogeny agar plates and spread using
sterile glass beads. Each of the 0.635 cm test discs were placed onto the plate using sterile
technique, coated side down, and plates were placed in the incubator overnight at 37°C.
Following incubation, plates were moved from the incubator, photographed, and the
resulting zones were measured.
ICP-MS analysis. All samples were prepared with deionized water, phosphate
buffered saline (PBS, 50mM sodium phosphate, 150mM NaCl, pH 7), sterile LB broth, or
DMEM medium. Medium (10 mL) was added to a sample tube, and test discs were
subsequently added to the bottom of each tube. Sample tubes were placed in the shaking
incubator at 37°C for ten-minute intervals. Following the incubation period, the media
was removed and an equal volume of fresh media was added to the sample tube; release
experiments were carried out over a one-hour period.
In the case of kinetics sample preparation, cells from 1 mL of culture from each of
the tubes used in the growth curve experiment were pelleted for 10 minutes at 6,000 RPM
in a Benchmark mini centrifuge. The supernatant from each of these tubes was placed
into a new sample tube, and was combined with 5% nitric acid. The pellet containing the
bacterial cells was discarded. All ICP samples were run against a standard prepared in
5% HNO3 containing 1,000 ppm silver nitrate (Ricca) calibrated to fit a linear curve
model and contain expected experimental outcome values.
Mammalian cell toxicity assays. NIH3T3 cells (American Type Tissue Culture,
Manassas, VA) were cultured in DMEM with 4.5 g/L glucose, L-glutamine, and sodium

pyruvate (10-013-CV; Corning, Manassas, VA) with 10% FBS (35-010-CV; Corning)
and 1% penicillin-streptomycin (P0781; Sigma-Aldrich, St. Louis, MO). NIH3T3
(1.5x106 cells) were plated in a six-well plate approximately 12 hours before adding discs
and incubated at 37°C with 5% CO2. Titanium only (control) or silver-coated titanium
discs were gently placed into the wells at the indicated time points before collection.
Media was removed and centrifuged to pellet any non-adherent cells; adherent cells were
gently trypsinized and pooled with the non-adherent cells for each sample. Cells were
collected and stained using an Annexin-V/PI kit (630109; Clontech, Mountain View, CA)
and FACs analysis was performed to determine the percentage of apoptotic cells.
Statistical analysis. Student’s t-test was performed to determine statistical
significance for the mammalian cell in vitro toxicity assays. All t-tests were performed as
a comparison to the value for apoptotic cells in the titanium control after 72 hours of
incubation. A p-value < 0.05 was considered statistically significant.
Results
Deposition and characterization of AgO films. The result of the microstructural
imaging of a 500 nm thick sample on a titanium foil substrate is shown in Figure 2. In the
50 kx image, the lighter regions contain voids at the grain boundaries probably associated
with the underlying defects in the cold-worked titanium foils used for substrate materials.
Lower oxygen concentrations during deposition yield larger grains and better-defined
grain boundaries than the image shown. However, we have no direct evidence that the
variations in microstructure impacts the performance of these materials.

Effect of AgxO coated discs on bacterial growth in solution. Based on the
previous findings of AgxO coatings exhibiting antimicrobial activity in solution,
measurements were extended to a more detailed analysis of coating properties on
efficacy. Figure 3 shows the growth curves of various bacterial species (E. coli, S.
aureus, P. aeruginosa, and K. pneumoniae) in the presence of an uncoated Ti disc or a Ti
disc coated on both sides with ~ 150 nm thick AgxO film. In each case, the culture
containing the titanium disc exhibited growth comparable to the control culture. In
contrast, the cultures containing the AgxO-coated discs showed significantly lower OD600
values for all bacteria tested. These curves indicate that the AgxO coating is eluting from
the surface of the disc into solution, inhibiting bacterial growth in all bacterial species.
Additionally, this inhibition was almost immediate upon addition of the AgxO coated disc
to the bacterial culture, indicating the rate of release high enough to very quickly reach a
threshold concentration of Ag+ in the culture to inhibit growth. These experiments were
extended to include bacterial cultures with different initial bacterial cell densities and the
results were similar (Figure 9).
The design of the experiments in Figures 3 and 9 involve the addition of the AgxO
coated disc to a bacterial culture in very early log-phase growth (OD600 < 0.1). However,
it was of interest to examine how these eluting coatings would behave in actively
growing mid-log cultures. As such, AgxO coated discs or Ti controls were added to
cultures of S. aureus or E. coli well into log-phase (Figure 10). The results show that the
addition of the disc at time 0 caused rapid inhibition of the planktonic culture. The
cessation of bacterial growth indicated by a plateau in the OD600 was generally seen
between 30 - 60 minutes after the addition of the disc. Additionally, aliquots of the

culture at the final time point (t = 3 h) exhibited growth on LB plates, indicating that the
Ag+ released into the culture was sufficient to exhibit bacteriostatic activity but not
bactericidal activity (data not shown).
The ability of the Ag+ to elute from the coatings and inhibit bacterial growth in
solution is a promising step toward the development of coatings for device applications.
Next, the properties of these coatings to prevent bacterial growth on surfaces, was
investigated using a modified Kirby-Bauer zone of inhibition (ZOI) approach. Briefly, Ti
discs or discs coated with Ag or AgxO films were placed on agar plates seeded with
known amounts of bacteria. These plates were incubated and the ZOI was measured
following 18 hours of growth (Figure 4). The presence of a ZOI indicates that the Ag+
ions from the coating eluted and inhibited bacterial growth with this zone. The Ti control
disc and the Ag-coated discs both exhibited no measurable ZOI, indicating that the pure
silver coatings were unable to elute and diffuse through the solid agar medium to any
significant concentration able to prevent bacterial growth. For this reason, as well as the
cost of material, pure Ag+ coatings were used minimally in liquid culture assays (data not
shown). In contrast, the AgxO coated discs clearly caused a ZOI, ranging from 0.8 - 1.0
cm in diameter. This inhibition of bacterial growth around the disc clearly indicates that
Ag+ is eluting from the disc at high enough concentrations to inhibit bacterial growth.
Silver ion release into culture media. The results above and from previous
work46, 57 support the hypothesis that the antimicrobial activity of the AgxO coatings is
directly tied to the elution of Ag+ from the films. This was further examined by preconditioning fresh culture media by incubating an AgxO coated disk in media for a fixed
amount of time before adding a bacterial inoculum. Figures 5A and B show the growth

curves of E. coli and S. aureus in media that was incubated with AgxO-coated discs for
variable times. In both cases, media that was pre-incubated for the longest times (30, 60,
120, 240 minutes) prevented the growth of the inoculated bacteria. In the case of S.
aureus, the 6-minute pre-incubation did not elute enough silver into the media to
completely inhibit bacterial growth. However, it is notable that the growth profile of S.
aureus was significantly inhibited, lagging well behind the growth profile of the
untreated control culture. These results indicate that the release rate of Ag+ from the
AgxO films is sufficiently fast to reach a threshold concentration in solution to inhibit
bacterial growth.
The bacterial cultures grown in pre-conditioned media were investigated to
determine if the Ag+ acted in a bactericidal (killing bacteria) or bacteriostatic (inhibiting
bacterial growth) mechanism. At selected time points during the course of the growth
curves, a small aliquot of the culture was removed and spotted onto LB-agar plates,
which were incubated for 18 hours to allow bacterial growth (Figure 5C). If the Ag+ is
acting as a bacteriostatic agent, the bacteria should become viable upon removal from the
Ag-containing culture and grow on the solid media while a bactericidal action would
leave no viable bacteria to grow on the plate. Strikingly, the preconditioned media
exhibited different mechanisms for the Gram-negative E. coli (Spots 1-6 in Figure 5C,
taken at 3h time point in the growth curve) compared to the Gram-positive S. aureus
(spots 7-12, Figure 5C taken at 3h time point in the growth curve). The concentrations of
Ag+ in solution were bactericidal for E. coli but were bacteriostatic for S. aureus.
Aliquots from the cultures were also plated corresponding to different time points (0 and
6h) in the growth curve and similar results were found (Figure 12).

The release of Ag+ into the pre-conditioned growth media solution was further
characterized by inductively coupled plasma mass spectrometry (ICP-MS). ICP-MS is
capable of detecting metals and certain non-metals in very low solution concentrations
(<0.1 ppm). The results of ICP-MS on LB media that was pre-conditioned for the same
time intervals are shown in Figure 5D. These results clearly show an increasing Ag+
concentration as a function of time, indicating continual release. The longest time point
(240 min) exhibits a similar concentration as the previous (120 min) indicating this may
be near the saturation point for this media type.
The effect of release rate was also examined by modifying the size of the coated
disc used in the experiment. The release rate of Ag+ will be directly dependent on the
surface area of the disc, that is, the surface area exposed to the media and nucleation sites
for release. This was performed by exchanging 0.3175 cm diameter discs for the 0.635
cm diameter used in previous experiments, while keeping the composition of the coating
the same. Figure 11 shows by decreasing the surface area, a 0.3175 cm disc did not
prevent bacterial growth, however by adding two or more 0.3175 cm discs to the same
culture, the bacterial growth inhibition was restored.
The concentration of Ag+ in the pre-conditioned media indicated a timedependent release profile, consistent with our previous findings. This was extended to
examine the effect of environment on the release rates, as the majority of previous reports
focused on the release profile in water, while in vitro cellular experiments take place in
much more complex media. Figure 6 demonstrates the cumulative silver release in water
and various media types as measured by ICP-MS. The results show that the Ag+ elutes at
a faster rate in water compared to the more complex media tested (LB used for bacterial

growth experiments and DMEM used for mammalian cell growth conditions).
Interestingly, the release rate of simple phosphate buffered saline (PBS) is slower than
water but faster than the complex growth media. The overall trend of release rates is H2O
> PBS > LB ≈ DMEM. The release rates calculated from these experiments and statistics
are included in the supplement (Table 1).
Silver absorption by bacteria. The results in the previous experiments show that
the eluted silver ions are the driving force behind the antimicrobial activity. This was
extended to investigate the association of eluted Ag+ to bacteria in solution. Starting with
cultures used in the growth curve experiments in Figure 3, a portion of the culture was
pelleted, dissolved in 5% nitric acid, and subjected to ICP-MS analysis. In all cases,
bacteria exposed to AgxO coated discs displayed significantly higher silver content in the
pelleted cells compared to titanium controls (Figure 7). This indicates the Ag+ ions are
stably associated with or are being taken up by the bacteria. It should be noted that the
cell pellets for the AgO treated samples were very small compared to the control, as the
number of viable cells was much smaller. Additionally, while there was some variability
between samples, all bacteria tested exhibited approximately the same amount of Ag
associated.
AgxO cytotoxicity in mammalian cell culture. Ag+ ions have been shown to be
toxic to mammalian cells at certain concentrations61. Therefore, it was of interest to
determine whether AgxO discs and the eluted Ag+ from these discs are toxic to murine
fibroblasts (NIH3T3 cells) in vitro. Cells (1.5 x 105) were seeded in 6-well plates in
complete media. Cells were incubated with either no disc, uncoated Ti disc, or AgxO
coated Ti discs for the indicated times, and apoptosis was analyzed using the Annexin-V

assay. Figure 8 shows that apoptosis significantly increased by 48 hours in cells
incubated with discs coated with 150 nm films on one or both sides of the disc.
Interestingly, the percentage of apoptotic cells appears to plateau at approximately 40%
in both cases. Of note, it was observed microscopically that cells immediately
surrounding the disc showed signs of cell stress prior to cells located distally to the disc,
which is likely due to an increased local concentration of Ag+ ions after or during elution
(data not shown). Collectively, these data suggest that high silver concentration in the
local environment eventually becomes toxic to the local cells.
Discussion
Overall, the experimental results presented show a distinct and rapid inhibition of
bacterial cell growth in planktonic culture and on surfaces due to the presence of AgxO
coatings. This inhibition is clearly linked to the ability of coatings to elute silver ions into
solution, or the local environment. The concentration of Ag+ eluted into solution was
directly dependent on the size of the eluting surface, exposure time, and the composition
of the coating46, 57.
As mentioned previously, silver has been used as a method for sterilization for
thousands of years62. Notably, in that time, there has been limited development of
resistance to silver33. The lack of resistance development is credited to the ability of
silver to induce response in a variety of targets in bacterial cells, both membrane and
cytoplasmic; multiple bacterial targets also contributes to silver’s broad-spectrum
activity34, 57, 63-64. In reported cases of increased silver resistance, the main determinant
involves a periplasmic metal-binding protein, a chemiosmotic efflux pump, and ATPase

efflux pump65-66. These plasmid-encoded pumps, which actively transfer the Ag+ out of
the cell, are thought to be a major cause of silver resistance65-66. The development of
silver resistance is not widespread, which can be attributed to the broad-spectrum activity
and the proposed mechanisms, which target multiple bacterial components63. Although
resistance to silver is a possibility, the rate of development appears to be slower than
alternative antimicrobial agents, which gives promise to future development of silverbased antimicrobial therapies in combinatorial and mixed-therapy applications67.
However, one of the main limitations to using silver as an antimicrobial agent or in
combination approaches has been the limited solubility of pure silver metal in aqueous
solutions46. Our previous work and that presented here show a viable strategy for
developing silver-based coatings that circumvent the solubility issue through the use of
silver oxide.
Coating implants is a widely investigated method of reducing bacterial
contamination following orthopedic surgeries. The complexities of these surgeries, which
are often complicated by trauma-related injuries, have yielded a number of different
strategies for controlling infection both during treatment and post-surgery. One of the
most common treatments in traumatic injuries is the use of antibiotic-loaded bone
cement, which is commonly used to fix implants and release a large burst of antibiotics to
the localized area in order to prevent infections. Due to the amount of antibiotic loaded
into the cement, after the initial burst, the release occurs slowly and over a prolonged
period of time; prolonged exposure to antibiotic dosages below the inhibitory
concentration is a large contributing factor to the spread of antibiotic resistance68-69. The
AgxO-based coatings described in this work, if applied to a surgical or medical device,

would maintain the antibacterial activity seen in the traditional antibiotics in bone
cements, while decreasing the resistance development threat70. In addition, the silver
oxide coatings are capable of being applied to a wide variety of surfaces and devices not
limited to bone cement. The release profiles of silver in complex environments (Figure 6)
indicate that sufficient silver will be released to be clinically viable as an antimicrobial in
a wound site, as opposed to the amount used in nanoparticle studies71 0.35 ppm – 1.12
ppm in our study, compared to 60 ppm - 250 ppm Ag nanoparticles.
Silver nanoparticles have also been commonly used as an efficacious and
practical way to coat surfaces; recent advances in nanotechnology have afforded the
ability to vary the size of the particles, and the physical characteristics of the particles,
and the of the dissolution/elution profile72. However, nanoparticle coatings have a distinct
set of limitations, based on the fabrication methodology, including inherent variability in
material composition. The use of nanoparticles has also shown variability in their toxicity
profile, due to the variability in material composition73-74. Nonetheless, nanoparticles do
provide a straightforward route to biologically active silver, although this route is often
confounded by variability in elution rates, the mechanical properties of the nanoparticles,
and the ability to adhere the nanoparticles to surfaces.
The majority of recently reported work utilizing Ag+ compounds as antimicrobials
incorporates the use of nanoparticles; in fact, 30% of total nano-products are nano-silver
particles60. Nanoparticles have become a popular alternative material for the creation of
antimicrobial coatings on medical devices and bandages. Although copper, zinc,
titanium75, magnesium, gold76, and alginate77 have all been tested for activity, silver
nanoparticles have proven the most efficacious against a wide range of bacteria and

viruses72. When three types of nanoparticles were compared in a growth curve analysis to
AgNO3 as a positive control, only the highest concentrations of both colloidal and
biogenic nanoparticles were able to inhibit growth comparable to the positive control in
both Gram-positive and Gram-negative bacterial species78. Concentrations of Ag+ the
aforementioned study ranged from 0.47 µg/mL – 0.53 µg/mL, with the lowest of those
showing no antimicrobial activity78. In comparison, the concentrations in the study
presented here ranged from 0.35 µg/mL – 1.12 µg/mL, and showed comparable
antimicrobial efficacy for both Gram-positive and Gram-negative species at 0.52 µg/mL
(equivalent to 30 minutes of release in LB).
Numerous studies have shown that nanoparticle delivery of Ag+ is more toxic to
mammalian cells than delivery via Ag-coated biomaterials79-80. Therefore, novel methods
for coating biomaterials with various Ag compounds in order to control Ag+ release have
been investigated57, 81. Numerous in vitro and in vivo studies have recently been
performed using various Ag-coated materials and have demonstrated antibacterial
efficacy in the absence of mammalian cell cytotoxicity82-88. Our in vitro cytotoxicity
results demonstrate that our coatings show cytotoxicity only in a portion of the cell
population at 48 hours (Figure 8). Microscopic analysis demonstrated that toxicity was
apparent in the cells immediately surrounding the disc and not cells located distally,
suggesting that that the local concentration of Ag+ is higher than the rest of the culture
(data not shown). Preliminary in vivo results show that subcutaneous implantation of the
AgxO-coated titanium discs in mice does not result in a detectable increase in Ag+ in
blood compared to controls up to 21 days (data not shown). Collectively, these data
suggest that in a “closed system”, such as a tissue culture plate, that accumulation of Ag+

ions can become cytotoxic, which was also suspected by another group in their model
system87. However, in an “open system”, such as an animal, removal of Ag+ from the
local environment via circulation can reduce or eliminate cytotoxic effects. Additional in
vivo experimentation to investigate the toxicity of these particular coating compositions is
warranted.
Previous work has shown that AgxO coatings created via reactive sputtering
methodologies are vastly superior to nanoparticle materials with regard to uniformity of
coating morphology, and exhibit a significantly higher elution rate of silver57, 89. The
elution rate is the key determinant of antimicrobial efficacy, as silver concentration in
solution causes bacterial cell death or bacterial growth arrest32. This was confirmed by
ICP-MS experiments that were linked to bacterial growth assays (Figures 3, 5, and 7).
The results presented here clearly show that the amount of Ag+ released from the coatings
is linked to the antimicrobial activity, and our initial results indicate that the Ag+
concentration in solution is also linked to the bactericidal vs. bacteriostatic mechanism of
action of Ag+ (Figures 5 and 12). The results indicate that ~3.24 µM Ag+ in solution is
sufficient to exert bactericidal activity against E. coli. This is a lower concentration when
compared to published reports stating that 18.9 µM Ag+ is required for complete
inhibition of growth90. On the other hand, our data shows that even at the highest final
concentrations (10.38 µM Ag+ – 4h time point), silver was acting as a bacteriostatic agent
against the Gram-positive species, S. aureus. This bacteriostatic activity is in agreement
with several reports in the literature, however the mechanism of bactericidal vs.
bacteriostatic activity was not reported in any of the publications where Ag concentration
was directly measured91-93.

The difference in bacterial response to Ag+ in both Gram-negative and Grampositive bacterial species is evident in the work presented, yet has been previously
studied in an attempt to better understand silver’s antimicrobial mechanism. When strains
of S. aureus and E. coli were exposed to Ag+, a cellular stress response led to the
condensation of DNA into the center of the cell, cell membrane detachment from the cell
wall, cell wall damage, cell shrinkage, and dehydration for both strains94. Although
damage to the cells appeared similar, E. coli (Gram-negative) sustained more extensive
structural damage than S. aureus (Gram-positive)94. Hypotheses for reduced
susceptibility of Gram-positive bacteria to Ag+ are rooted in the composition of the cell
wall of Gram-positive bacterium, which is slightly more negatively charged due to a
larger presence of peptidoglycan, and therefore thought to trap some Ag+ in the cell
wall95. Observations from various studies were confirmed in the data presented in Figures
5 and 12; Ag+ induces a bacteriostatic effect in Gram-positive bacteria, and a
bacteriolytic effect in Gram-negative bacteria94, 96-98. While bacteriostatic agents leave the
infectious particles intact, it provides a limitation to increase infection scope, and can
provide opportunities for combinatorial approaches to clear the infection, including
additional administered therapeutics or allowing time for the host immune system to clear
the infection.
Conclusion
In this study, silver oxide was applied to titanium foil to test antimicrobial activity
as a proof of concept for medical device applications. The coatings were deposited using
a reactive sputtering method that allows the process to be carried out at room
temperature, making large-scale manufacturing process and applicability to alternative

substrates viable options for future application46, 57. In addition, the sputtering method can
be adjusted to produce variability in coatings including chemical composition and
adjustable elution rates46, 57, 99. Coatings can be developed and tailored via composition
changes or the creation of distinct, multi-layered systems in which each layer of the
coating has different chemical compositions and/or elution profiles for Ag+. In addition to
the layering capability, homogeneous coatings of varied chemical compositions can also
be used to modulate elution profiles.

Figure 2. SEM image of a mixed phase sample of silver oxide deposited at 20 mTorr in a
67/33 mixture of Ar/O2 on a titanium foil substrate. This film is approximately 500 nm
thick.

Figure 3. Antibacterial activity of AgxO coatings in liquid culture. Ti or Ti coated with
AgxO (~150 nm double-sided) discs were added to cultures of (A) S. aureus (starting
density ~3.93 x 106 CFU/mL), (B) E. coli (starting density ~3.73 x 107 CFU/mL), (C) P.
aeruginosa (starting density ~3.53 x 107 CFU/mL) and (D) K. pneumoniae (starting
density ~3.43 x 106 CFU/mL). Symbols are (p,) for AgxO-coated discs, (u) for
untreated control, and (n) for uncoated titanium disc control.

Figure 4. Zone of inhibition assay. Images of LB plates seeded with, (A) S. aureus (B)
E. coli, (C) P. aeruginosa, and (D) K. pneumoniae. The AgxO disc (labeled AgO on the
plates) exhibited ZOI of (A) 0.9 cm for S. aureus, (B) 1 cm for E. coli, (C) 0.8 cm for P.
aeruginosa, and (D) 0.8 cm for K. pneumoniae. Diameter of the disc in each case is 6.5
mm (1/4”). No ZOIs were evident for Ag-coated or Ti control discs.

Figure 5. Growth curve analysis in media pre-conditioned by exposure to AgxO coated
(150 nm, double-sided, 1/4”) discs. (A & B) Data shown are (a) S. aureus at an initial
density of ~1.22x105 CFU/mL and (b) E. coli at an initial density of ~1.34x106 CFU/mL.
(C) Plating of aliquots of cultures from the 3h time point on LB agar plates (E. coli
shown in 1-6, S. aureus shown in 7-12); time stations as follows: 0 min. spots 1,7; 6 min.
spots 2,8; 30 min. spots 3,9; 60 min. spots 4,10; 120 min. spots 5,11; 240 min. spots 6,12;
(D) ICP-MS analysis of LB media after incubation with AgxO discs for fixed time points
corresponding to pre-conditioning time points in (A & B).

Figure 6. ICP-MS analysis of Ag+ released from Ti discs with a single-sided 150 nm
thick AgxO coating in (A) water, (B) PBS, (C) LB broth, and (D) DMEM for each media
type. Data shown are averages of 3 replicates and error bars represent standard
deviations. Note the difference in timescale for (A) compared to (B-D).

Figure 7. ICP-MS analysis of Ag+ from growth curve samples shown in Figure 3.
Samples were removed at the end of the 6h time course. Black bars represent samples
taken from cultures treated with the uncoated Ti discs while the gray bars represent
samples treated with AgxO-coated Ti discs. Error bars represent ranges for AgxO samples
based on the replicate from each bacterial strain.

Figure 8. Mammalian in vitro toxicity assays. NIH3T3 (1.5 x 106 cells) were plated and
cultured for approximately 12 hours. Discs were then added for the indicated time points,
then cells collected and stained with Annexin-V and PI. (A) ~150 nm coating, doublesided or (B) ~150 nm coating, single-sided discs - all 0.635 cm discs. Assays were
performed in triplicate and the averages are graphed with standard deviations.
*p-value < 0.05.

Figure 9. Effect of initial culture density on antimicrobial efficacy. Titanium or titanium
coated with AgxO (~150nm double sided) discs were added to cultures of (A) S. aureus
and (B) E. coli. Samples indicated are (u) 1:3 dilutions, (p) 1:10 dilutions, () and
1:100 dilutions.

Figure 10. Effect of increased culture density on antimicrobial efficacy. Titanium or
titanium coated with AgxO (~150nm double sided) discs were added to cultures of (A) S.
aureus (starting concentration of 3.46x106 CFU/mL), (B) E. coli (starting concentration
of 3.06x106 CFU/mL), (C) P. aeruginosa (starting concentration of 3.70x106 CFU/mL)
and (D) K. pneumoniae (starting concentration of 5.06x105 CFU/mL) after extended
growth before additions. Samples indicated are (p) AgxO-coated discs, (u) untreated
control, and (n) titanium disc.

Figure 11. Growth curve analysis using varying numbers of 1/8” AgxO-coated test discs
for (A) and (B) E. coli, and (C) and (D) S. aureus. In figures (A) and (B), curves are
shown for a single 0.3175 cm piece, as well as up to five test discs in a single tube; in
both the cases of S. aureus and E. coli, adding more discs to the test tube decreased the
bacterial concentration in the tube. Bacterial concentrations for E. coli experiments
ranged from 5.23x107 – 1.07x108 CFU/mL, S. aureus concentrations ranged from
6.66x106 - 1.02x107 CFU/mL.

Figure 12. Spot platings for both bacterial species at varying time points during the preconditioned media assay. E. coli is represented at (A) 0 hours, and (C) 6 hours, while S.
aureus is shown at (B) 0 hours and (D) 6 hours.

Table 1.
Ag+ Elution Rates in Various Types of Media.
Media Type

Elution Rate (ppm/min)

R2 Value

7.55E-02
+
0.00711
1
Water
LB Broth
4.55E-03
+
0.00107
1
DMEM
3.65E-03
+
0.000608
1
PBS
3.34E-02
+
0.00578
1
Note. Calculated elution rates as well as R2 values from a linear fit are shown for each
media type. Values were calculated based on three ICPMS runs for each media type.

Chapter 3
Efficacy of Silver Oxide Coatings In Vivo
Introduction
As surgical practices have advanced, so has the ability of the medical community to
combat surgical complications, including infection (most notably those caused by
surgical implants). For years, the instances of infections after orthopedic surgeries were
low, yet recent studies have shown that the risk for post-surgical infection is
increasing100. Antibiotic resistance and the continued ability for bacteria to overcome
antibiotic treatment is a likely explanation for an increase in infections in medicine, most
notably in healthcare settings2, 4. As such, it has become a goal of both the medical and
scientific communities to develop alternative treatments to reduce the occurrence of postoperative infections, most of which occur on the surface of the implant. Targeting
bacterial adhesion is a common strategy in preventing biofilm formation, which occurs
when microorganisms attach to a surface and embed in a matrix of secreted proteins,
nucleic acids and polysaccharides101. Biofilms are often more resistant to treatments, and
can exacerbate the effects of the infection102. In the United States alone, an estimated 1.7
million healthcare-acquired infections each year are caused by biofilms, accounting for
$11 billion in healthcare costs5, 103; it is estimated by the CDC and NIH that 65-80% of
infections can be attributed to biofilms104.
Silver has been known as an antimicrobial agent for centuries, but its use decreased
with the rise in the use of antibiotics in the late 1900’s. Yet the rise of antibiotic resistant
organisms has renewed interest in the use of silver compounds for this purpose. Silver
resistance has been identified, yet the majority of silver resistant bacteria were isolated

from environments in which silver and other metals were naturally-occurring32 as well as
reports in clinical environments and wounds treated with silver nitrate32. Upon further
research, the silver resistance mechanism was found to be very similar to that of other
metal-resistance mechanisms, and in that way, has been widely studied32, 105. The primary
mechanism of silver resistance is linked to metal efflux pumps, which export silver out of
the bacterial cytoplasm105-106.
Coating orthopedic implants with silver nanoparticles has become somewhat
common, yet recent data suggests that silver oxide formulations are more efficacious
against microbial organisms, as well as less toxic towards mammalian cells than
nanoparticles55, 79. The use of coatings at the surface of an implant rather than systemic
antibiotic treatment to control post-operative infection is ideal to prevent selection of
antibiotic-resistant pathogens.
Preliminary studies were conducted on AgxO-coated discs to assess antimicrobial
efficacy in solution. It was found that silver coatings eluted Ag+ from the surface of
coated titanium discs in sufficient concentration to kill various bacteria. It was also
previously shown that there was limited toxicity against mammalian cells in in vitro
assays. While useful in determining toxicity of agents, in vitro assays are limited in that
they are a closed system, which does not accurately recapitulate a dynamic and
exchanging in vivo environment. In contrast, the mammal is an open system, capable of
removing molecules, including silver ions, from a local area to reduce concentration
and/or eliminate the molecule from the system.

The goal of this study was to determine the efficacy of AgxO-coated titanium discs in
preventing bacterial adhesion in a mouse model of infection. This was done by
subcutaneous implantation of AgxO-coated discs in mice, and subsequent injection of a
specified amount of fluorescent bacteria to induce probable infection.
Materials and Methods
Bacterial culturing. Luminescent bacteria, S. aureus (Xen-36), E. coli (Xen-16),
P. aeruginosa (Xen-5) (Perkin Elmer, Waltham, MA) were streaked onto LB - Miller
agar (Difco) plates from frozen glycerol stocks, grown overnight at 37°C in a nonhumidified chamber, and stored at 4°C.
To prepare overnight liquid cultures, a single colony of each bacterial strain was
added to 3 mL LB broth (Difco) in sterile culture tubes. Tubes were placed in a shaking
incubator at 37°C overnight to allow for sufficient bacterial growth. Following the
incubation period, dilutions of the overnight culture were prepared in Muller-Hinton
broth (Criterion) 1:100; changing broth provides for better short-term bacterial growth
and is comparable to MIC assay protocols.
Bacterial growth analysis. Protocol followed is explained in Chapter 2, Materials
and Methods section labeled ‘Bacterial culturing’.
ICP-MS analysis. All ICP samples were compared against a standard prepared in
5% HNO3 containing 1,000 ppm silver nitrate (Ricca) calibrated to fit a linear curve
model and containing expected experimental outcome values. Media collected from the
in vitro toxicity assays was analyzed in order to assess silver content in 5 mL DMEM
with a starting concentration of 1.5x105 cells.

For mouse blood sample preparation, approximately 100 µL of blood was
collected into a centrifuge tube containing 50 µL of 5% sodium citrate via submandibular
bleeding at the indicated times post-surgery. Cells were pelleted at 5,000 RPM for 5 min,
and 100 µL of supernatant was added to 3 mL of 5% HNO3. Samples were then analyzed
by ICP-MS in order to determine serum silver concentration.
In vivo bacterial adhesion assay. Mice were anesthetized using 5% isoflurane in
O2 for induction and 1-3% isoflurane in O2 for maintenance. A 5.5 cm long, 2.5 cm deep
incision was made on the back flank of mice and a subcutaneous “pocket” created. A
AgxO-coated or titanium uncoated 1 cm x 2 mm titanium disc was inserted into the
“pocket” and the incision closed with surgical staples. PBS or one of three luminescent
variants of clinically relevant pathogens, S. aureus, Xen-36 (105 CFU), E. coli, Xen-16
(107 CFU), and P. aeruginosa, Xen5 (105 CFU) (Perkin Elmer), were then introduced
into the area near the surgical “pocket” by subcutaneous injection of the biomaterial
using a needle for precision. Temperature and body condition of the mice were monitored
daily.
Results
Effect of silver-coated discs on bacterial growth. AgxO coatings were
previously tested on non-luminescent varieties of common healthcare-acquired bacterial
strains to determine coating thicknesses and efficacy in solution (Chapter 2).
Luminescent bacterial strains were used to provide the option of imaging the mice to
observe the infection, as well as obtaining luminescent readings for bacterial cultures

after the disc removal. Previous experimentation confirming the antimicrobial efficacy of
the test discs was performed with non-luminescent bacterial strains.
Figure 13 shows the growth curves of various luminescent bacterial species (S.
aureus, E. coli, P. aeruginosa - provided by Perkin Elmer) in the presence of a titanium
disc, or a 150nm AgxO coated double-sided disc, one replicate made from two different
batches. (Double-sided discs are coated with the indicated silver formulation on both
sides of the disc; single-sided discs are only coated on one side.) The cultures containing
the coated discs exhibited growth inhibition when compared to the control culture and the
titanium cultures, as well as reproducibility between batches. The results from this
experiment match previously reported data, as outlined in Chapter 2.
Toxicity of AgxO coatings in NIH3T3 cell lines. Previous results demonstrated
that exposure to either a 150nm double- or single-sided disc induces apoptosis of
NIH3T3 cells in culture. Figure 14 shows that silver ions consistently eluted from the
discs (both double sided, A, and single sided, B) over the course of the experiment.
Importantly, silver ion concentration continued to rise in the media over the time course
examined (data not shown).
Establishing the in vivo bacterial adhesion assay. In order to determine whether
AgxO coatings can limit or reduce bacterial infection in vivo, a mouse model of infection
was established. Mice were anesthetized and injected with buprenorphine; titanium discs
were then placed subcutaneously, the wound was closed using surgical staples, and the
mice were injected subcutaneously with PBS or a culture of a luminescent bacterial
strain, as indicated. Mice were live-imaged at various points post-surgery to visualize

luminescent bacteria and X-ray imaging was performed to visualize the mice. Bacteria
could be detected in vivo by 4 days post-surgery (Figure 15A, 15C, 15D). However, the
immunocompetent mice were able to clear the infection by 2 weeks (Figure 15B). Pilot
studies were performed with immunocompromised mice under the supervision of the
attending veterinarian; regular monitoring of the mice indicated hypothermia in a high
number of infected animals, which required immediate euthanasia to prevent imminent
death107. Therefore, all subsequent experiments were performed in immunocompetent
mice with 2-4 days of infection. Discs were retrieved from euthanized mice and cultured
in LB to determine the presence of bacteria (Figure 15E); OD600 and luminescence
measurements demonstrate that the bacteria adhering to the disc are the injected
luminescent bacteria and not an opportunistic infection (Figure 15F).
Determining the safety of AgxO-coated discs in vivo. In vitro studies suggested
that AgxO-coated titanium discs are toxic to mammalian cells, as reported in Chapter 2.
Of note, it appeared that the cells closest to the disc died first, while those distal to the
disc did not show signs of apoptosis by 72h (data not shown). These data suggest that the
local concentration of silver ions may be high enough to induce apoptosis in a closed
system. However, this is not indicative of an in vivo system, since animals are capable of
clearing silver ions from the local area and excreting them from the organism. Therefore,
whether Ag+ can be detected in the serum of mice implanted with AgxO-coated discs was
evaluated. Figure 16 shows that there were no detectable increases in silver ion
concentration in mice implanted with AgxO-coated discs compared to control mice
implanted with an uncoated titanium disc. Interestingly, there was no indication of tissue
damage in mice implanted with the AgxO-coated discs up to 21 days post-surgery

(Figures 17B and 17C) as compared to those implanted with titanium controls (Figure
17A). However, long-term toxicity studies will have to be performed in order to
determine the feasibility of using AgxO formulations in the clinic.
Discussion
Overall, the experimental results presented show the ability of AgxO-sputtered
discs to inhibit luminescent bacterial growth, as well as their limited toxicity in cellular
culture. Observed toxicity was confined primarily to the immediate area surrounding the
disc, suggesting that testing in a closed system is not indicative of in vivo results. In
addition, in vivo testing produced an infection model in immunocompetent mice as well
as methodology to remove and quantify bacterial adhesion on the implanted disc. When
blank discs were replaced with AgxO discs in the mouse bacterial adhesion model, blood
samples were removed from test animals and silver concentrations were found to be
similar in both the control subjects and test subjects three weeks post-surgery.
In vitro experiments demonstrate that Ag+ eluting coatings do result in some level
of toxicity to mammalian cells. The antimicrobial activity is directly linked to Ag+
concentration in solution, and reports in the literature indicate that silver ion
concentration can result in mammalian cell toxicity61, 108. To address the concentrationtoxicity relationship, we analyzed silver concentrations by ICP-MS from in vitro cell
culture experiments (Figure 14). When compared, the single-sided discs (Figure 14B)
produced silver concentrations approximately half that of the double-sided discs (Figure
14A), and at all time points including AgxO-sputtered discs Ag+ content was relatively
equal, indicating that at 24h the culture has reached saturation. As reported previously,

the double-sided discs had a reported maximum toxicity of approximately 40% at the 72h
time point (Chapter 2) and an average Ag+ content of 8.63 +/- 0.333 ppm. In the same
respect, the single-sided discs had a reported maximum toxicity of approximately 36% at
the 48h time point and an average Ag+ content of 3.68 +/- 0.691 ppm. In both cases, the
apoptotic cells were located in immediate proximity to the test disc, indicating that in
open systems, toxic effects may be minimized. When compared to a similar study, silver
nanoparticles were used to determine both IC50 and total lethal concentrations of Ag+ in
NIH3T3 cells; these concentrations were found to be 72 ppm and 86 ppm, respectively61.
When compared to the experimental values, even the higher concentration, double-sided
discs were eight times below the LC50 value.
In an effort to extend the in vitro toxicity studies to an in vivo system, both
immunocompetent and immunocompromised mice were implanted with uncoated
titanium discs and injected with various luminescent bacterial strains. Mice were imaged
to further identify the scope of any bacterial infections, although in some cases, evidence
of infection was observed before imaging. Figures 15A and 15B show mice infected with
S. aureus, in which half of the test mice were able to clear the infection before imaging
(Figure 15B). The optimal imaging period was determined to be 2-4 days in the
immunocompetent model for S. aureus, P. aeruginosa (Figure 15C) and E. coli (Figure
15D) mice. None of the immunocompromised mice were imaged; shortly after surgery,
the majority of infected mice showed symptoms of hypothermia indicating likely
systemic infection and imminent death, so the mice were euthanized and experiments
with immunocompromised mice discontinued. Further investigation in
immunocompromised models will require an adjusted bacterial load and a different

immunocompromised mouse model. Following imaging, discs were extracted and
cultured at 37°C overnight in order to quantify bacteria (Figure 15E). OD600 and
luminescent measurements were performed on the cultures (Figure 15F); luminescence
confirms that the bacteria attached to the disc are the injected bacteria and not an
opportunistic infection. Culturing of the implanted discs confirms that the bacteria were
viable, as well as reinforces the previous findings that the effects of AgxO on E. coli is
bactericidal, while S. aureus is bacteriostatic.
There are various in vivo models that can be utilized to study infection, including
non-mammalian models, such as C. elegans109. For the purposes of these studies, it was
concluded that a mammalian model, mice in particular, would yield the most translatable
data. There are numerous infection models that can be employed in mice, including
central venous catheter models, subcutaneous foreign body infection models,
intraperitoneal foreign body infection models, urinary tract infection models, ear, nose
and throat infection models, respiratory tract infection models, and osteomyelitis
infection models109. The subcutaneous foreign body infection model was utilized in these
studies, as this is the least invasive and least technically challenging of the models
indicated above. In addition, this is the best system out of those listed above for inserting
the coated discs that have been utilized in this study thus far. For example, the coated
discs could not be inserted in an intraperitoneal foreign body infection model. In the
future, it is possible that additional systems will be utilized. For example, coating of
catheters and using the urinary tract infection model or the central venous catheter model
may be utilized.

Following the previously established protocol, AgxO-sputtered discs were inserted
into mice to assess toxicity and Ag+ levels in the blood. Following blood draws at various
time points post-surgery, ICP-MS analysis of samples obtained from mice containing
uncoated Ti discs and AgxO sputtered Ti discs confirmed that there was no difference in
silver content in the blood between both groups. This confirms the ability of silver to be
readily removed from the body in an open system. Extensive studies have been
completed on the oral toxicity of silver in both murine and rat models, which provide
some insight into the levels of silver ions that cause systemic toxicity in each model.
Following oral doses of silver nanoparticles in a murine model, silver was detected nearly
system-wide, in the liver, kidneys, brain, skin, pelt, spleen, eyes, muscles, blood, small
intestine, stomach, lungs, bladder, prostate, tongue, teeth, salivary glands, thyroid,
parathyroid, heart, pancreas and duodenum44, 79, 104, 110-120. In a separate study conducted
with rats, tissue accumulation of silver was found to be dose-dependent following an
initial oral dose80. Further experimentation is required to assess if subcutaneous
administration of silver will yield a similar system-wide presence in a murine model, as
well as if certain organs will be more affected by the presence of silver than others.
Conclusion
Follow-up experiments are currently demonstrating that the coatings are more
efficacious against Gram-negative compared to Gram-positive bacteria. These results are
consistent with previous results showing the tendency for AgO to be bacteriostatic to
Gram-positive and bacteriolytic to Gram-negative bacteria. Additionally, further
experimentation in the murine infection model should provide further insight into the
excretion methods of silver from the body, as well as potential specific organ toxicity.

Figure 13. Effect of initial culture density on antimicrobial efficacy. Titanium or
titanium coated with ~150nm AgxO double-sided discs were added to cultures of (a) S.
aureus (Xen-36) (starting concentration: 1.10x105 CFU/mL), (b) E. coli (Xen-16)
(starting concentration: 2.13x106 CFU/mL), and (c) P. aeruginosa (Xen-5) (starting
concentration: 1.71x106 CFU/mL).

Figure 14. Silver concentration following exposure to various discs and times. Uncoated
or AgxO coated titanium discs, (a) 150nm double-sided or (b) 150nm single-sided, were
added to 1.5x106 NIH3T3 cells in a 6-well plate for the indicated times and cellular
toxicity determined by Annexin-V assay. Media was collected at each time point and
analyzed by ICP-MS for silver ion concentration. Assay was performed in triplicate.
*p-value < 0.05.

Figure 15. Detection of luminescent bacteria in vivo. Pilot studies were performed in
order to determine the ideal infectious time frame for determining efficacy of the coated
discs in vivo. Mice were subcutaneously implanted with uncoated titanium discs and
injected with PBS, S. aureus (Xen-36), E. coli (Xen-16), or P. aeruginosa (Xen-5), as
indicated. Mice were imaged using an MS/FX-Pro at 2 weeks (D) or 4 days (A, B, C)
post-surgery. Mice were euthanized, and discs were retrieved and cultured in 5 mL LB
overnight at 37°C. Representative culture samples from S. aureus (Xen-36) injected mice
from panel A are shown (E); (F) graphical representation of OD600 and luminescent
measurements of samples from panel E.

Figure 16. Blood analysis of mice subcutaneously implanted with AgxO-coated discs.
Five mice were subcutaneously implanted with titanium control discs or double-sided
150 nm AgxO-coated discs. Blood samples were obtained at various days following
surgery and analyzed by ICP-MS to determine serum silver concentration.

Figure 17. AgxO coated discs do not appear to cause damage to cutaneous tissue.
Approximately six weeks post-surgery, mice implanted with AgxO coated discs showed
no obvious signs of cutaneous tissue damage (B & C) compared to uncoated control discs
(A). Inset (C) shows a closer view of the discs on the tissue.

Chapter 4
Extension of Silver Oxide Coatings to Materials for Biomedical Applications
Introduction
When dealing with coatings for medical devices or other medical settings, an
important aspect of development is the ability to control the elution rate of an active
component from the surface. This is applicable to coatings that are designed to elute an
active component, as well as those coatings that are intended to remain static on the
surface. Many factors influence the desired elution rate: surface substrate, intended
bacterial targets, type of implant, and coating composition. It has thus far been observed
that AgxO is a viable candidate for coating surfaces and/or implants to provide
antimicrobial functionality. In an attempt to further control the elution rate of Ag+,
formulations can be manipulated to contain additional components to modulate Ag+
elution. By using mixed compositions to create new antimicrobial coatings, the activity,
toxicity, biocompatibility, and cost of manufacturing will be affected.
In addition to being a favorable candidate for implant coatings, silver could also
be considered for other aspects of healthcare as a partial or full antibiotic replacement.
One such viable example is that of a liquid bandage, yet the delivery solvent, dependent
on the specific application, could vary. Currently, liquid bandages are commonly made of
octyl-2-cyanoacrylate, a longer-chain cyanoacrylate approved by the FDA specifically for
this purpose, although many researchers have tried to alter the structure to provide more
flexibility121. A variety of biomaterials are candidates for such applications, due to their
biodegradability and biocompatibility with host extracellular matrix, which gives them
the distinct ability to be recognized and accepted by the human body122-123. These

biodegradability and biocompatibility properties, along with the variety of naturally
derived biomaterials, provide a viable and diverse set of scaffolds as substrates for drug
delivery.
Silks are an example of biomaterials that are used widely in textile manufacturing
due to their strength124. The silk fibroin proteins in particular exhibit greater durability
compared to many other biomaterials, providing the possibility of longer-term
applications47. The durability of silk-based materials can be manipulated, adding a level
of tunability for specific applications. Silk fibroin proteins are derived from Bombyx mori
silkworms, and adopt a functional hetero-dimeric beta-sheet structure. The hetero-dimer
consists of two proteins, a heavy chain (~370 kDa), and a light chain (~26 kDa), which
are covalently connected through a disulfide bond. The anti-parallel beta-sheet structure
in the hetero-dimer is formed primarily from 12 repeating hydrophobic motifs124-129
(Figure 18). The strength and materials properties of silk proteins have been extensively
studied, and were found to be as strong as, or in some tests stronger than, synthetic highperformance polymer fibers125-129. In addition, the silk fiber is coated by a secondary
protein known as sericin, which acts as an adhesive between fibers, but can also be
manipulated for material applications130. Given the compositional flexibility, durability,
and biodegradability of silk fibroin polymers, they can likely be combined with other
proteins, such as elastin, to form complexes suitable for biomedical purposes.
Bandages are a ubiquitous example of a simple medical device used to ameliorate
the effects of abrasions and lacerations in both hospital and home settings to help prevent
infection. Often, commercially available bandages are supplemented with topical
antibiotics as bacitracin zinc, neomycin sulfate, polymyxin B, or some combination of

these, yet recent studies have shown that these antibiotic-loaded bandages are not as
effective at reducing bacterial loads in wounds as previously believed131-132. Continued
use of these antibiotic-impregnated bandages will likely contribute to increased resistance
development, and hence render them less effective over time. Silver-coated bandages
have often been applied in the treatment of burn wounds27, 133-134 yet recently, these
silver-coated bandages have been considered as an alternative to traditional antibiotic
bandage coatings in the treatment of standard abrasions and incision wounds135-136. As
such, the antimicrobial efficacy of these bandages will be directly linked to the elution
rate of Ag+ or Ag-containing compounds from the bandages to the wound site.
As mentioned previously, the antimicrobial properties of metals such as mercury,
arsenic, silver, and copper have been known for years, but were often overlooked with
the dawn of the age of small molecule antibiotics137. Of these metals, silver is currently
the most widespread in antimicrobial applications, yet copper has also garnered
significant interest for antimicrobial properties. Metallic copper surfaces have been
widely examined for their contact killing abilities, which were proven effective against a
variety of bacterial species138. When investigated as a coating for surfaces, copper and
copper alloys showed significant bacterial inhibition against both E. coli and MRSA at
various bacterial loads139. However, like silver, copper has limited solubility in aqueous
environments, thus limiting the ability to elute active Cu+/Cu2+ into a wound site.
Mixtures of CuO and AgxO present the potential advantage of modulating release rate of
Ag+ ions into solution, because CuO is effectively insoluble in water. This would allow
facile synthesis of mixed AgxO/CuO layers, in which the relative ratios of the
components are varied to tune elution properties. Noting the elution profiles of

substances used is important to maintain the antimicrobial activity of the coatings
themselves, as well as eliminate any potential toxicity induced by elution that occurs too
quickly140-141.
The goal of the following studies was to utilize AgxO in similar ways to those
previously tested in an attempt to widen the potential market for AgxO coating
technology, as well as further understand and utilize the ability to alter the elution
profiles of formed coatings. To do this, coatings were embedded in silk fibroin proteins,
applied to standard bandages, and combined with CuO to test and compare efficacy to
standard AgxO coatings in similar assays as those completed in previous chapters.
Materials and Methods
Generation of silk films and silk film deposition. To extract silk proteins, raw
cocoons were cut and washed, rinsed with sodium carbonate, and boiled, as reported
previously124. Extracted fibers are rinsed multiple times and dried in an oven. The dried
fibers are dissolved in LiBr solution and subjected to dialysis against water to further
separate the silk fiber proteins. The sample is then centrifuged, and concentration
determined by dry weight analysis128.
To create impregnated films, the desired amount of solid AgO or Rhodamine 6G
was added to silk solution and dissolved by mixing. Aliquots of these solutions were
added to individual wells of 96-well plates and were dried using ambient airflow in a
chemical fume hood overnight. The following day, films were twice rinsed with methanol
to solidify the film and prevent flaking during experimentation. The creation of multilayered films followed the same procedure in sequence.

Rhodamine release assay. A specified amount of PBS was added to each of the
test wells containing silk films, regardless of composition, and the plate was placed in the
incubator at 37°C for 1 hour. Following incubation, a portion of the PBS solution in each
well was transferred to a fresh 96-well plate for fluorescence reading.
Bacterial culturing. Protocol followed is explained in Chapter 2, Materials and
Methods section labeled ‘Bacterial culturing’.
Modified minimum inhibitory concentration (mMIC). The modified version of
the broth micro-dilution assay was used to determine the antimicrobial activity of the
silver impregnated silk films. This is modified, as silver is not added in solution, but it is
present in a solid film at the bottom of the well, thus restricting the soluble silver in the
wells. The modified MIC plates were prepared with AgO-impregnated silk containing
varying concentrations of AgO in the films (ranging from 0%-0.5% by weight). To each
coated well, 200µL of bacterial culture (0.5x105 CFU/mL), or blank LB broth was added,
providing test replicates as well as controls for each concentration of AgO film. Plates
were covered and placed in the incubator at 37°C overnight. Following incubation, plates
were removed from the incubator and photographed before 100µL was transferred from
each well into a fresh 96 well plate. Absorbance measurements were performed on these
100µL aliquots at 600nm using a Molecular Devices Spectramax M5. An additional
aliquot of 50µL was removed from selected wells from the original plate and spread onto
LB agar plates. These LB agar plates were incubated at 37°C overnight and colonies were
counted following incubation to assess growth and investigate bactericidal vs.
bacteriostatic activity.

Bacterial growth curve analysis. Protocol followed is explained in Chapter 2,
Materials and Methods section labeled ‘Bacterial culturing’.
ZOI. Protocol followed is explained in Chapter 2, Materials and Methods section
labeled ‘Bacterial culturing’.
Results
Silk biopolymers as an antibacterial delivery platform. In order to examine the
ability of silk films to deliver silver oxide to kill bacteria, a fluorescent reporter,
Rhodamine 6G, was used to assay release from silk biopolymer films deposited in 96well plates. The films were constructed in a dual-layer format such that only one of the
two layers (top, bottom) contained the Rhodamine. This experiment was designed to
determine whether the Rhodamine release was affected by the exposure to the aqueous
environment and/or the presence of an additional blocking layer of silk biopolymer.
Results of this experiment, shown in Figure 19, show that there was greater release of
Rhodamine into the aqueous milieu when the Rhodamine-containing layer was the top
layer of the film. When the Rhodamine-containing layer was concealed by an undoped
silk biopolymer layer, release still occurred, but to a lesser extent.
Previous work has demonstrated that silver oxide is an effective antimicrobial
agent when applied as a surface coating to titanium; this coating component has been
extended to several alternative delivery methods. Figure 20 shows a sample 96-well plate
containing AgO-impregnated silk films at varying AgO concentrations. This image
shows that the films are relatively homogeneous at the macroscopic level with coloration
changes as AgO concentrations increase. A modified MIC (mMIC) for these types of

films was determined by incubating the films with bacterial cultures of either S. aureus
(Figure 21) or E. coli (data not shown). The mMIC for S. aureus was found to be
somewhat variable, ranging between 0.1% - 0.25% AgO. The results for E. coli, however,
are confounded by inherent antimicrobial activity from the silk, either from the
biopolymer itself or remnants of the purification process.
In addition to determining mMICs for AgO-impregnated silk films, films
impregnated with silver nanoparticles or films coated with AgO via reactive sputtering
were also examined. Figure 22 shows the results of the zone of inhibition assay using silk
films with each of the previously described compositions. Universally, consistent with
the mMIC findings, the measured ZOI for all compositions was larger against E. coli than
S. aureus. However, in both cases, the sputter-coated AgO performed similarly to
impregnated silver nanoparticles, both of which performed slightly better than AgOimpregnated films.
A comparison of these materials was also performed as a bacterial growth curve
analysis, as described above. The results show that all three silver/silk material forms
inhibited bacterial growth for both S. aureus and E. coli (Figure 23). As presented
previously, in this experimental environment, E. coli was showed greater inhibition
compared to S. aureus in both experimental duplicates as well as across impregnated
AgO, silver nanoparticles, and AgxO sputtered silk. In the cases of both the S. aureus and
E. coli, growth inhibition occurred with all silver-containing discs, although the Grampositive S. aureus experienced the most antibacterial activity from the silver-sputtered
silk discs.

Application of coatings formed by reactive sputtering applied to bandages. In
an effort to assess the antimicrobial properties of silver-sputtered bandages as compared
to standard, commercially available bandages (both antibiotic-coated and regular,
uncoated) zone of inhibition assays were performed with varying bacterial species
(Figure 24). In the cases of both the S. aureus and E. coli, uncoated bandages showed no
inhibition to bacterial growth on the surface, while the antibiotic-coated bandages showed
little to no growth. Although growth on the E. coli plate was less dense than S. aureus, a
zone of inhibition of decent size was present on each plate. In addition to surface
bacterial testing, solution kinetics testing was also performed to test the efficiency of
elution over a length of time (Figure 25). In the case of each bacterial species tested, the
test tubes containing AgO-coated bandages showed no increase in growth throughout the
length of the experiment, while the control, standard bandages, and antibiotic-coated
bandages all showed rapid growth increases. In all cases, there was little to no difference
between the control, regular, and antibiotic-coatings.
Evaluation of AgxO/CuO films as next-generation antimicrobial coatings. A
series of AgxO/CuO coatings in which the AgxO/CuO ratio was varied (Table 2),
deposited on high-density polyethylene (HDPE). These different film compositions were
tested for antimicrobial activity be performing zone of inhibition assays (Figure 26). All
compositions tested induced a zone of inhibition against S. aureus and E. coli, with the
exception of composition #71 (10 Ag, 70 Cu). These coatings were also tested in growth
curve experiments (Figure 27). In these experiments, the most effective compositions at
inhibiting bacterial growth were the mixtures that contained AgxO as the major
component. Composition #71 was ineffective against both bacterial species tested, and

composition #73 was more effective against S. aureus than E. coli, yet not as effective as
samples with higher silver oxide concentration.
Discussion
Overall, the experimental results presented show an inhibition of growth in
culture and on surfaces with various application methods of AgO (impregnated or
sputtered, etc.) as well as AgxO/CuO mixtures. The flexibility of surfaces on which AgxO
coatings and coating mixtures can be applied allows for a great number of future possible
applications.
Biomaterials provide a natural and biodegradable platform to deliver silver to
surface wounds, preventing bacteria from infecting the wound. Using films composed of
Mori silk provided a flexible, biodegradable material to deliver silver and potentially
other compounds. While the biopolymer films had exhibited favorable properties for
silver delivery, the process involved in creating the films, as well as materials properties
changes upon AgxO deposition by sputtering, may affect the future range of applications.
Specifically, the silk biopolymer films became very brittle after sputtering deposition,
which would limit the ways these materials could be molded for final application. In
addition, due to the poor solubility of AgO in water142, attaining a uniform distribution of
AgO in impregnated films was more difficult than anticipated (final results shown in
Figure 20). Whether or not universal distribution of AgO solid could occur in a different
concentration of silk solution was not investigated. While this non-uniform distribution
did not appear to affect the activity in our experiments, it may present challenges and
variability in behavior when scaled up. In the experiments performed, however, this

heterogeneous distribution was likely a result of the properties of silver oxide, as our
experiments with Rhodamine resulted in a more uniform coating and differential release
based on the multilayer structure (Figure 19). Rhodamine release was observed in both
cases, but the films that contained Rhodamine in the top layer, exhibited higher
fluorescence than those in which Rhodamine was embedded in the bottom layer. This
indicates that Rhodamine release from the lower layer was obstructed by the presence of
the second layer of silk, as expected. Using this methodology, we propose it would be
possible to deliver different amounts of AgO and control the rate of release, providing a
longer-lasting antimicrobial effect. Additionally, the experiments performed were a
single time point analysis, so determining the kinetics of release in these systems is also
of interest for future experiments.
The minimum inhibitory concentrations were determined for both S. aureus
(Figure 21) and E. coli using AgO-embedded silks deposited on the surface of a 96-well
plate. The value for S. aureus proved to be more difficult to determine than E. coli. This
is consistent with previous observations in which higher concentrations of AgO were
required for activity against S. aureus compared to E. coli. The heterogeneity in the AgOimpregnated silk films may result in batch-to-batch differences, resulting in differential
release of AgO into the wells, and thus potentially delivering below the concentration
required for activity in some replicates. Testing on bacteria-loaded surfaces (Figure 22)
and in solution (Figure 23) proved that in the majority of cases, AgO-impregnated silk
films provided equal efficacy as 0.1% silver nanoparticles, and 150nm AgO sputtered silk
films. In both solid and liquid culture, S. aureus proved more difficult to inhibit (Figure
22B, Figure 23B), consistent with our other findings. This held true for the silver

nanoparticles as well as the AgxO-sputtered pieces, however the silk impregnated pieces
showed greater growth reduction than all other test pieces.
The use of bandages is ubiquitous in the treatment of lesions, abrasions, and other
wound types. The ability of bandages to aid in wound healing is important in the
prevention of infection by providing a barrier between the open wound and the
environment. Many bandages also contain one of more standard small molecule
antibiotics to aid in infection control, however they are becoming increasingly unable to
fulfill this task, a new alternative is imperative131. Silver-coated bandages were examined
for antimicrobial efficacy on solid media (Figure 24) and in solution (Figure 25) and
compared to traditional, commercially available antibiotic-loaded bandages, as well as
standard bandages. Although the size of the bandages used in ZOI tests were somewhat
variable, it is evident from the data that the AgO-coated bandages were far superior in
inhibiting growth of S. aureus, shown in Figure 24A. The commercially available
antibiotic bandages were completely ineffective at inhibiting S. aureus growth, providing
a dramatic proof of concept in the potential efficacy of these coatings for bandage
applications. This trend can also be seen for E. coli in Figure 24B, although the initial
results are inconclusive due to the incomplete growth of a bacterial lawn on the plates.
The solution growth kinetics performed yielded similar results, as the AgO-sputtered
bandages showed a greater growth inhibition than the standard uncoated bandages or
commercially available antibiotic coated bandages. Further testing is necessary to
determine a sufficient the dose needed to inhibit bacterial growth at the wound site, as
well as the effects of those dosages to the immediate wound area, surrounding skin, and
overall wound healing process.

While exploring alternative ways to control the elution rate from AgO coatings,
mixing AgO with other known antimicrobials was proposed. AgO/CuO mixtures were
sputtered onto plastic substrates and tested as an alternative coating material. The
rationale was that the CuO is practically insoluble in water, and thereby could provide a
means of modulating the release of Ag+ from AgO-containing surfaces. ZOI testing was
performed on each of the six mixtures prepared, using both E. coli (Figure 26A) and S.
aureus (Figure 26B). All mixtures showed similar efficacy in producing a ZOI, except for
#71, the composition containing the least AgO in the mixture. Solution testing was
performed on each of the mixtures as well, against both E. coli (Figures 287A and 27B)
and S. aureus (Figures 27C and 27D). In these experiments, E. coli growth was inhibited
by each of the mixtures, while S. aureus only showed complete inhibition with mixtures
containing at least 30 Ag. From these results, it can be deduced that the AgO portion of
the mixtures provided the majority of antimicrobial activity in these cases, and CuO
appears to serve as a viable method to control the elution rate of Ag+. Future experiments
will focus on quantifying the release rates of Ag into solution from different AgO/CuO
mixtures, as well as determining the ability of the AgO/CuO films to prevent adhesion to
surfaces before and after all Ag+ is released into solution.
Conclusion
In these studies, various delivery methods of AgO were examined, as well as CuO
as an additive to AgO sputtered coatings as a way to control the elution rate of coatings
from the surface. Silk biofilms were used as a delivery method for impregnated AgO
solid, with future application to surface punctures and wounds as an alternative to
traditional bandages. In addition, AgO-coated bandages exhibited a greater antimicrobial

effect than that of the standard, commercially available antibiotic coated bandages,
indicating that they may become a viable alternative to standard bandages. Finally,
adding CuO to previously tested AgO formulations did not significantly effect the ability
to inhibit bacterial growth, however growth inhibition was dependent on AgO:CuO ratio
in the films. This is thought to be a result of CuO modulating the release rate of the AgO.
Finally, using AgO/CuO mixtures would make the technology more affordable, as Cu is a
less expensive material than Ag. In total, these varied applications and materials
demonstrate the flexibility of AgO coatings produced by reactive sputtering for a variety
of biomedical applications.

Figure 18. Secondary structure of one B. mori silk fibroin chain; (Gly-Ala-Gly-Ala-GlySer) amino acid repeat units that self-assemble into antiparallel beta sheets. Figure
modified143-144.

Figure 19. Rhodamine release comparison form multi-layered silk films. Rhodamine
fluorescence from the supernatant collected after exposure to multi-layered silk films.
Fluorescence measurements were taken of films composed of two layers of pure silk, a
layer of Rhodamine-impregnated silk on top of a layer of pure silk, and a layer of pure
silk over a layer of Rhodamine-impregnated silk. n=16.

Figure 20. Silk films deposited on the bottom of 96 well plate. Various concentrations of
silk/silver were deposited on the bottom of individual wells of a 96 well plate.
Concentrations are outlined in to highlight variations in silver concentration. Red – 0%
AgO, orange – 0.001% AgO, yellow – 0.005% AgO, green – 0.01% AgO, light blue –
0.1% AgO, dark blue – 0.25% AgO, purple – 0.35% AgO, pink – 0.5% AgO.

Figure 21. Modified minimum inhibitory concentrations for S. aureus. All MIC
concentrations were confirmed 2-4 times in varying replicates, and replicates are shown
as means with standard deviation over all wells tested containing films with the same
concentration of impregnated AgO.

Figure 22. Zone of inhibition analysis for various silk films containing silver. Zone of
inhibition for (a) E. coli and (b) S. aureus. Test discs containing 0% AgO (pure silk
control), 0.5% AgO (impregnated), 0.1% silver nanoparticles (impregnated), or 150nm
AgxO sputtered surface coating. Zone of inhibition measured for E. coli: exhibited a 1.6
cm zone for 0.5% AgO, 1.8 cm zone for 0.1% silver nanoparticles, 1.9 cm zone for the
AgxO sputtered surface, and no zone for the 0% AgO control. Zone of inhibition
measured for S. aureus: 1 cm zone for 0.5% AgO, 1.5 cm outer zone for 0.1% silver
nanoparticles, 1.6 cm outer zone for the AgxO sputtered surface, and no zone for 0% AgO
control. All test discs are 0.635 cm diameter. Plates were seeded with a known
concentration of bacteria, discs were applied to the surface and the plates were grown at
37°C overnight before measurement and imaging.

Figure 23. Growth curve analysis in solution. Silk film discs containing either 0% AgO,
0.5% AgO (green), 0.1% silver nanoparticles (orange), or AgxO 150nm sputtered (purple)
discs were placed into (a) E. coli (starting concentration of 1.25x106 CFU/mL), (b) S.
aureus (starting concentration of 1.17x105 CFU/mL). Data are color coded according to
replicates.

Figure 24. Zone of inhibition testing for various bandage types. Zone of inhibition for (a)
S. aureus and (b) E. coli. Standard, commercially-available uncoated bandages, antibiotic
coated (Polymyxin B Sulfate 10,000 units and Bacitracin Zinc 500 units per gram), and
AgxO sputtered bandages were tested. Plates were seeded with a known concentration of
bacteria, bandages were applied to the surface and the plates were grown at 37°C
overnight before imaging.

Figure 25. Growth curve analysis of bandages in solution. Standard uncoated, antibioticimpregnated (Polymyxin B Sulfate 10,000 units and Bacitracin Zinc 500 units per gram),
and AgxO sputtered bandages were tested for antimicrobial efficacy in solution. Strains
examined were: (a) S. aureus (starting concentration 1.13x107 CFU/mL), (b) E. coli
(starting concentration 1.51x108 CFU/mL), (c) P. aeruginosa (starting concentration
1.06x108 CFU/mL), and (d) K. pneumoniae (starting concentration 1.49x107 CFU/mL).
All test bandages were cut to approximately the same dimensions to minimize potential
differences in dosing.

Figure 26. Zone of inhibition testing for silver oxide/copper mixtures. Zone of inhibition
for (a) E. coli and (b) S. aureus. (A) exhibited no zone at 71, 1 cm zone at 73, 0.9 cm
zone at 75, 1 cm zone at 77, 1 cm zone at 81, and 0.8 cm zone at 79. (B) exhibited no
zone at 1, 1 cm zone at 73, 0.9 cm zone at 75, 1 cm zone at 77, 1 cm zone at 81, and 0.9
cm zone at 79. Concentrations for each composition are listed in Table 2.

Figure 27. Growth curve analysis of copper oxide/silver oxide mixtures. Coatings were
deposited on high-density polyethylene (HDPE). Uncoated pieces were used as the
control. Pieces were tested against (a, b) E. coli (starting concentrations 1.47x106
CFU/mL and 1.81x106 CFU/mL, respectively) and (c, d) S. aureus (starting
concentrations 1.24x105 CFU/mL and 1.47x105 CFU/mL, respectively). All test pieces
were squares approximately sized 3/16” per side. Coating composition varied from
sample to sample, and is described in Table 2. The numbers in the legend correspond to
the sample numbers in Table 2.

Table 2.
AgxO/CuO Coating Compositions.
Sample Number

Composition

71
73
75
77
79
81

10 Ag, 70 Cu
20 Ag, 60 Cu
30 Ag, 60 Cu
40 Ag, 50 Cu
50 Ag, 40 Cu
60 Ag, 30 Cu
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